Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Invested Capital: 2013-2025

Historic Invested Capital for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to $232.7 million.

  • Theravance Biopharma's Invested Capital rose 25.33% to $232.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $232.7 million, marking a year-over-year increase of 25.33%. This contributed to the annual value of $175.5 million for FY2024, which is 17.58% down from last year.
  • Latest data reveals that Theravance Biopharma reported Invested Capital of $232.7 million as of Q3 2025, which was up 3.48% from $224.8 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Invested Capital registered a high of $480.6 million during Q3 2022, and its lowest value of -$361.6 million during Q1 2021.
  • For the 3-year period, Theravance Biopharma's Invested Capital averaged around $226.6 million, with its median value being $213.0 million (2023).
  • Its Invested Capital has fluctuated over the past 5 years, first slumped by 128.93% in 2021, then surged by 254.50% in 2022.
  • Over the past 5 years, Theravance Biopharma's Invested Capital (Quarterly) stood at -$321.6 million in 2021, then spiked by 237.36% to $441.8 million in 2022, then crashed by 51.79% to $213.0 million in 2023, then declined by 17.58% to $175.5 million in 2024, then rose by 25.33% to $232.7 million in 2025.
  • Its last three reported values are $232.7 million in Q3 2025, $224.8 million for Q2 2025, and $166.0 million during Q1 2025.